Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading Down 8.3%

Shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) fell 8.3% on Wednesday . The company traded as low as $20.64 and last traded at $20.64. 1,491 shares were traded during mid-day trading, a decline of 81% from the average session volume of 7,957 shares. The stock had previously closed at $22.50.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Calliditas Therapeutics AB (publ) in a research report on Thursday, February 22nd.

Calliditas Therapeutics AB (publ) Trading Down 4.4 %

The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89. The company has a fifty day moving average price of $21.46 and a two-hundred day moving average price of $20.57. The firm has a market capitalization of $641.08 million, a price-to-earnings ratio of -13.12 and a beta of 1.50.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. Calliditas Therapeutics AB (publ) had a negative return on equity of 104.47% and a negative net margin of 38.72%. The business had revenue of $42.45 million for the quarter, compared to analyst estimates of $36.24 million. During the same quarter in the previous year, the firm earned ($0.01) EPS. As a group, research analysts forecast that Calliditas Therapeutics AB will post 0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Deutsche Bank AG lifted its position in Calliditas Therapeutics AB (publ) by 26.5% in the first quarter. Deutsche Bank AG now owns 90,509 shares of the company's stock valued at $2,170,000 after buying an additional 18,978 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Calliditas Therapeutics AB (publ) by 7.6% in the 3rd quarter. Jane Street Group LLC now owns 12,491 shares of the company's stock worth $191,000 after acquiring an additional 886 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Calliditas Therapeutics AB (publ) by 1,270.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company's stock worth $51,000 after purchasing an additional 3,112 shares during the period. Finally, Optiver Holding B.V. acquired a new stake in Calliditas Therapeutics AB (publ) in the 4th quarter valued at approximately $25,000. 2.83% of the stock is currently owned by institutional investors and hedge funds.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.